

S/N 09/847,042

COPY OF PAPERS  
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael R. Leadbetter et al.

Examiner: Unknown

Serial No.: 09/847,042

Group Art Unit: 1646

Filed: May 1, 2001

Docket: 1343.002US1

Title: GLYCOPEPTIDE PHOSPHONATE DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants further request that a copy of the 1449 form, initialed by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

RECEIVED

MAR 12 2002

TECH CENTER 1600/2900

Respectfully submitted,

MICHAEL R. LEADBETTER ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 359-3265

Date

2-25-02

By

Robert J. Harris, Ph.D.  
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 26 day of February, 2002.

Alisia G. Dunbar

Name

Signature

S/N 09/847,042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael R. Leadbetter et al.

Examiner: Unknown

Serial No.: 09/847,042

Group Art Unit: 1646

Filed: May 1, 2001

Docket: 1343.002US1

Title: GLYCOPEPTIDE PHOSPHONATE DERIVATIVES

PATENT

TECH CENTER 1600/2900

MAY 08 2002

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants are submitting herewith International Patent Application Publication Number WO 00/54751 (in German) with an English abstract included on the front page. Applicants submit that the English abstract is a concise explanation of the relevance of International Patent Application Publication Number WO 00/54751, as required under 37 C.F.R. 1.98(a)(3). Accordingly, the Examiner is respectfully requested to acknowledge consideration of International Patent Application Publication Number WO 00/54751.

Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

MICHAEL R. LEADBETTER ET AL.


By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 359-3265

Date

4-30-02

By



Robert J. Harris, Ph.D.  
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 30<sup>th</sup> day of April, 2002.

Alisia G. Dunbar

Name

Signature